What makes Cochrane’s new AI study innovative?
Cochrane has released a pre-print of the protocol for our innovative study that will test whether artificial intelligence (AI) tools can support or enhance evidence synthesis. Gerald Gartlehner from Cochrane Austria, Principal Investigator for the study, discusses how the study works, and what makes it interesting.
Anti-amyloid Alzheimer’s drugs show no clinically meaningful effect
Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new Cochrane review has found.
Cochrane Methods Executive seeks new Methods Group Convenor representative
We seek nominations for one upcoming vacant position on the Cochrane Methods Executive, to start in September 2026. Please note the deadline for nominations is Friday, 29 May 2026.
Celebrating 10 years of Cochrane Russia: a decade of collaboration and impact
Image Members of Cochrane Russia at a workshop in Kazan When Cochrane Russia was established in 2015, it began as a coordinating hub fo
Simple antiseptic can reduce newborn infections
A new Cochrane review finds that chlorhexidine likely cuts umbilical cord infection rates by about 29% in low- and middle- income countries, and may reduce newborn deaths.
Rupa Sarkar joins Cochrane as Editor in Chief
The Cochrane Collaboration is delighted to announce that Rupa Sarkar starts today as the new Editor in Chief.
Cochrane launches webinar series on GRADE methodology
Cochrane is launching a new eight-part series of Cochrane Learning Live webinars designed to help systematic reviewers understand and apply the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) framework in evaluating the certainty of evidence in their systematic reviews.
Cochrane announces selected AI tools for innovative platform study
Cochrane has confirmed the two artificial intelligence (AI) tools selected to take part in our innovative platform study evaluating how artificial intelligence could support and enhance key stages of evidence synthesis.
Celebrating 10 years: the story behind Cochrane Taiwan
Over the past 10 years Cochrane Taiwan has built a reputation for mobilizing knowledge and promoting evidence-based medicine both in Taiwan and beyond. Here they share some of the successes and learnings that have stood out over the past decade.
How did Cochrane select AI tools to evaluate in our platform study?
Cochrane has launched an innovative study to test whether artificial intelligence tools can support or enhance evidence synthesis. We only have scope to evaluate two, and so a selection process was required. Here, we outline that process and demonstrate what Cochrane values when deciding whether to use an AI tool for evidence synthesis.
News
News
Trusted evidence.
Informed decisions.
Better health.
Informed decisions.
Better health.
11-13 Cavendish Square
London
W1G 0AN
United Kingdom
The Cochrane Collaboration is a charity (no. 1045921) and a company limited by guarantee (no. 03044323) registered in England & Wales. VAT registration number GB 718 2127 49.
Copyright © 2026 The Cochrane Collaboration